The Anaplastic Lymphoma Kinase (ALK) is aberrantly is rearranged or mutated in several tumors including inflammatory myofibroblastic tumor (IMT), anaplastic large-cell lymphoma (ALCL), neuroblastoma, inflammatory myofbroblastic tumor and nonsmall cell lung cancer (NSCLC) patients. Here, ALK is linked to neuroblastoma.